A single centre, open label, study to assess the safety, tolerability and biodegradation of PA5108 ocular implant in adults who have Open Angle Glaucoma (Primary or Secondary).
Participants who are currently managing their Open Angle Glaucoma with combination drop therapy will be recruited. Drop therapy will cease in the treatment eye and continue in the contralateral eye. The treated eye will receive via injection, a single PA5108 ocular implant. Participants will be monitored for safety and tolerability of the ocular implant until it completely biodegrades.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
8
single ocular implant, administered on day 1
Centre for Eye Research Australia
East Melbourne, Victoria, Australia
Melbourne Eye Specialists
Melbourne, Victoria, Australia
Safety and tolerability as measured by the occurrence of adverse events
Time frame: 4 weeks
Timeframe to complete implant biodegradation based on implant size and location
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.